Xenon Pharmaceuticals (XENE) Enterprise Value (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Enterprise Value of -$1.1 billion for Q1 2026, down 99.18% year-over-year from -$133.4 billion in Q1 2025, and down 16.99% quarter-over-quarter from -$935.8 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Enterprise Value (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Enterprise Value for 14 consecutive years, with -$1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 99.18% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 99.18% YoY), while the FY2025 annual figure was -$935.8 million, down 49.27% from the prior year.
- Enterprise Value slipped to -$1.1 billion in Q1 2026 per XENE's latest filing, from -$935.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$526.7 million in Q3 2023 and bottomed at -$1.1 billion in Q1 2026.
- Historically, Enterprise Value has averaged -$703.5 million across 5 years, with a median of -$638.2 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 202.56% — and 2023, when it jumped 31.54%.
- Xenon Pharmaceuticals' Enterprise Value stood at -$592.1 million in 2022, then retreated by 7.77% to -$638.1 million in 2023, then grew by 1.75% to -$626.9 million in 2024, then slumped by 49.27% to -$935.8 million in 2025, then dropped by 16.99% to -$1.1 billion in 2026.
- Business Quant data shows XENE's Enterprise Value at -$1.1 billion in Q1 2026, -$935.8 million in Q4 2025, and -$913.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -930.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -930.69 Mn |
| Mar 31, 2026 | -1.09 Bn |
| Dec 31, 2025 | -935.76 Mn |
| Sep 30, 2025 | -913.01 Mn |
| Jun 30, 2025 | -977.01 Mn |
| Mar 31, 2025 | -549.63 Mn |
| Dec 31, 2024 | -626.91 Mn |
| Sep 30, 2024 | -654.02 Mn |
| Jun 30, 2024 | -721.54 Mn |
| Mar 31, 2024 | -699.60 Mn |
| Dec 31, 2023 | -638.08 Mn |
| Sep 30, 2023 | -526.67 Mn |
| Jun 30, 2023 | -539.60 Mn |
| Mar 31, 2023 | -527.04 Mn |
| Dec 31, 2022 | -592.09 Mn |
| Sep 30, 2022 | -638.19 Mn |
| Jun 30, 2022 | -788.24 Mn |
| Mar 31, 2022 | -537.94 Mn |
| Dec 31, 2021 | -551.77 Mn |
| Sep 30, 2021 | -249.63 Mn |